1 – 28 of 28
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Airway hyperresponsiveness correlates with airway TSLP in asthma independent of eosinophilic inflammation
2024) In Journal of Allergy and Clinical Immunology(
- Contribution to journal › Article
- 2023
-
Mark
Eosinophils and tissue remodeling : Relevance to airway disease
(
- Contribution to journal › Scientific review
-
Mark
Clonal evolution and stereotyped sequences of human IgE lineages in aeroallergen-specific immunotherapy
(
- Contribution to journal › Article
-
Mark
Airway hyperresponsiveness reflects corticosteroid-sensitive mast cell involvement across asthma phenotypes
(
- Contribution to journal › Article
-
Mark
Plasma proteins defending infected, intact nasal mucosa
(
- Contribution to journal › Letter
- 2022
-
Mark
Epithelial repair in asthma : Defect or exaggerated?
(
- Contribution to journal › Letter
- 2021
-
Mark
Allergome-wide peptide microarrays enable epitope deconvolution in allergen-specific immunotherapy
(
- Contribution to journal › Article
- 2020
-
Mark
Gain-of-function mutation in complement C2 protein identified in a patient with aHUS
(
- Contribution to journal › Letter
- 2019
-
Mark
IL-33 drives influenza-induced asthma exacerbations by halting innate and adaptive antiviral immunity
(
- Contribution to journal › Article
-
Mark
The SQ tree SLIT-tablet is highly effective and well tolerated : Results from a randomized, double-blind, placebo-controlled phase III trial
(
- Contribution to journal › Article
-
Mark
Airways exudation of plasma macromolecules : Innate defense, epithelial regeneration, and asthma
(
- Contribution to journal › Article
-
Mark
IL-33 blockade affects mediators of persistence and exacerbation in a model of chronic airway inflammation
(
- Contribution to journal › Article
- 2018
-
Mark
Toll-like receptor 3 blockade in rhinovirus-induced experimental asthma exacerbations : A randomized controlled study
(
- Contribution to journal › Article
-
Mark
Lytic eosinophils produce extracellular DNA traps as well as free eosinophil granules
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Substance P represents a novel first-line defense mechanism in the nose
(
- Contribution to journal › Article
-
Mark
Viral induced overproduction of epithelial TSLP : Role in exacerbations of asthma and COPD?
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Intralymphatic immunotherapy with 2 concomitant allergens, birch and grass : A randomized, double-blind, placebo-controlled trial
(
- Contribution to journal › Letter
- 2017
-
Mark
Antibody-encoding repertoires of bone marrow and peripheral blood-a focus on IgE
(
- Contribution to journal › Letter
-
Mark
Effectiveness of bronchial thermoplasty in patients with severe refractory asthma : Clinical and histopathologic correlations
(
- Contribution to journal › Article
-
Mark
The number and affinity of productive IgE pairs determine allergen activation of mast cells
(
- Contribution to journal › Letter
-
Mark
Epithelial perviousness in allergic airways disease
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Diminished airway macrophage expression of the Axl receptor tyrosine kinase is associated with defective efferocytosis in asthma
(
- Contribution to journal › Letter
-
Mark
Eosinophilic airway inflammation in asthmatic patients is associated with an altered airway microbiome
(
- Contribution to journal › Article
-
Mark
Major differences between human atopic dermatitis and murine models, as determined by using global transcriptomic profiling
(
- Contribution to journal › Article
-
Mark
Analysis of Safety and Tolerability Data in Pediatric Patients with Primary Immunodeficiency Diseases from Two Phase 2/3 Studies of Human Immune Globulin Subcutaneous, 20%
2017) 2017th AAAAI Annual Meeting In Journal of Allergy and Clinical Immunology 139(2, Supplement). p.217-217(
- Contribution to journal › Published meeting abstract
-
Mark
A New Subcutaneous Immunoglobulin 20% Formulation (SCIG 20%) with Individualized Infusion Parameters Resulted in a Positive Safety and Tolerability Profile in Patients with PIDD in Europe and North America
2017) 2017th AAAAI Annual Meeting In Journal of Allergy and Clinical Immunology 139(2, Supplement). p.216-216(
- Contribution to journal › Published meeting abstract
-
Mark
Best Possible Treatment for All Patients with Primary Immune Deficiency (PID) in Sweden Regardless of Social Factors, Sex, Age or Residence
2017) 2017th AAAAI Annual Meeting In Journal of Allergy and Clinical Immunology 139(2, Supplement). p.249-249(
- Contribution to journal › Published meeting abstract
- 2016
-
Mark
Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2 : A cohort study
(
- Contribution to journal › Article